Haemoglobinopathies congenital Terminated Phase 2 Trials for Alemtuzumab (DB00087)

Also known as: Haemoglobinopathies / Haemoglobinopathy / Hemoglobinopathy / Hemoglobinopathies / Haemoglobinopathy NOS / Abnormal hemoglobin NOS

IndicationStatusPhase
DBCOND0026458 (Haemoglobinopathies congenital)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00040469Bone Marrow Transplant From Related Donor for Patients With High Risk HemoglobinopathiesTreatment
NCT00040417Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk HemoglobinopathiesTreatment